The global liver fluke treatment market is estimated to register growth at a healthy CAGR of around 4% to 5% during the forecast period 2022-2032. Increasing research and development activities aimed at developing more effective therapeutic drugs for the treatment of liver-related diseases are projected to create growth prospects in the liver fluke treatment market over the forthcoming years.
| Report Attribute | Details |
| Liver Fluke Treatment Market Projected Growth Rate (2022-2032) | 4% to 5% CAGR |
Liver fluke is a collective name of a polyphyletic parasitic trematodes group that infect humans as well as animals and cause ailment related to the liver and bile duct. These parasitic worms are commonly categorized into 2 types of infection-causing worms and termed as Fasciola Gigantica and Fasciola Hepatica, which is also known as sheep liver fluke.
Fascioliasis is an infectious disease caused by these parasites that results in severe abdominal pain, fever, hives, malaise, diarrhea, and others. Many times liver fluke infections go undiagnosed or misdiagnosed with general abdominal pain. However, growing awareness regarding the severity of the disease and the introduction of novel treatments is favoring the growth in the market.
Over the last decade, the prevalence of infectious diseases such as liver fluke is growing at a rapid pace. This is due to the declining global immunity and rising consumption of salads comprising water-based leaves such as watercress, resulting in fueling the demand for associated diagnostics and treatment solutions.
For instance, according to the survey by the American Journal of Tropical Medicine and Hygiene, nearly 2.6 million people are estimated to be affected by fascioliasis and around 91 million people are at the risk of developing the infection across the world. As liver fluke therapeutics drugs such as praziquantel, triclabendazole, bithionol, albendazole, and nitazoxanide among others play a vital rise in the treatment of fascioliasis, rising burden of these infectious diseases is expected to drive the sales in the global market.
There are numerous side effects related to the consumption of liver fluke treatment drugs such as praziquantel, albendazole, and nitazoxanide including itching, fever, dizziness, hair loss, vomiting, discolored urination, and others. Growing awareness regarding these side effects in hindering the sales in the market.
Also, stringent approval policies and regulations regarding the launch of novel liver fluke treatment solutions across various countries are further restraining the growth in the market.
Future Market Insights reveals that East Asia is estimated to account for a lion’s share in the global liver fluke treatment market from 2022 to 2032.
With increasing emphasis on increasing the export of meat, wool, livestock, and others, the government of several countries are focusing on undertaking several initiatives to increase the breeding and population of cattle such as sheep.
For instance, as per the Food and Agriculture Organization, the population of sleep was reported to reach 16.58 Mn by 2019, exhibiting a year-on-year growth of around 1.2%. As sheep are highly prone to liver flukes, growing sheep population is projected to create lucrative opportunities in the East Asia market.
As per a study by FMI, North America is anticipated to emerge as a highly remunerative market for liver fluke treatment during the forecast period 2022-2032.
A number of players in the market are focusing on developing and launching novel therapeutic drugs with minimal side effects and aiming at receiving product approval to cater to the surging demand for effective liver fluke treatment solutions in North America.
For instance, in 2019, Novartis, a global healthcare company, announced receiving Food & Drug Administration approval for its new liver fluke treatment drug, Egaten (triclabendazole), for patients six years of age and older in the U.S. A multiplicity of such developments is expected to drive the growth in the North America market.
Some of the leading players in the liver fluke treatment market are Novartis, GlaxoSmithKline Plc., Merck & Co., Inc., Pfizer Inc, Bayer HealthCare Pharmaceuticals Inc., Par Pharmaceutical, Romark Laboratories, L.C., Lupin Pharma, Schering Corporation among others.
Attributed to the presence of such high number of participants and increasing research and development activities for novel liver fluke treatment drug, the market is highly competitive.
| Report Attribute | Details |
| Growth Rate | CAGR of 4% to 5% from 2022 to 2032 |
| Base Year for Estimation | 2021 |
| Historical Data | 2015-2020 |
| Forecast Period | 2022-2032 |
| Quantitative Units | Revenue in USD Billion, Volume in Kilotons and CAGR from 2022-2032 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered |
|
| Countries Covered |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
By Drug Type:
By Route of Administration:
By Application:
By Distribution Channel:
By Region:
FMI projects the sales of liver fluke treatment in the market is expected to rise at 4% to 5% value CAGR by 2032
The global liver fluke treatment market is expected to be dominated by East Asia over the forecast period 2022-2032.
Novartis, GlaxoSmithKline Plc., Merck & Co., Inc., Pfizer Inc, Bayer HealthCare Pharmaceuticals Inc., Par Pharmaceutical, Romark Laboratories, L.C., Lupin Pharma, Schering Corporation, and others are some of the leading players in the key liver fluke treatment market.
Explore Similar Insights
Liver Fluke Treatment Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
